Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884648 | 0.94 | CA14 (0.40) | CA1CA12CA14HDAC6CA7 | |
| SCHEMBL27947608 | 0.93 | HDAC1 (0.39) | CA1CA12CA14HDAC6CA7 | |
| SCHEMBL27868897 | 0.93 | HDAC1 (0.39) | CA1CA12CA14HDAC6CA7 | |
| SCHEMBL27662317 | 0.93 | HDAC1 (0.39) | CA1CA12CA14HDAC6CA7 | |
| SCHEMBL28085982 | 0.93 | HDAC1 (0.39) | CA1CA12CA14HDAC6CA7 | |
| SCHEMBL1512279 | 0.88 | CA14 (0.43) | CA1CA12CA14HDAC6CA7 | |
| SCHEMBL8310669 | 0.85 | CA14 (0.41) | CA1CA12CA14HDAC6CA7 | |
| SCHEMBL27942277 | 0.83 | HDAC6 (0.37) | CA1CA12CA14HDAC6CA7 | |
| SCHEMBL27910088 | 0.81 | TDP1 (0.46) | CA14HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL5287476 | 0.81 | HDAC6 (0.39) | CA14HDAC6HDAC1HDAC2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-09 | — | — | US | disclosed |
| EP-3694836-B1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB SHANGHAI CO LTD (CN) | 2022-06-15 | — | — | EP | disclosed |
| WO-2019072237-A1 | PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2019-04-18 | — | — | WO | disclosed |
| CN-103717589-B | For treating or prevent the compound of respiratory syncytial virus disease | 弗·哈夫曼-拉罗切有限公司 | 2016-08-17 | — | — | CN | disclosed |
| EP-1363873-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| CN-102766142-A | Lactam compounds useful as protein kinase inhibitors | MILLENIUM PHARMACEUTICALS INC | 2012-11-07 | — | — | CN | disclosed |
| CN-101068815-B | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| CN-102656174-A | Compounds for the treatment of hepatitis C | BRISTOL MYERS SQUIBB CO | 2012-09-05 | — | — | CN | disclosed |
| CN-102015717-A | Chemokine receptor modulators | ALTIRIS THERAPEUTICS | 2011-04-13 | — | — | CN | disclosed |
| CN-1617859-A | 5-sulfanyl-4H-1, 2, 4-triazole derivatives and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2005-05-18 | — | — | CN | disclosed |
| CN-1599739-A | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2005-03-23 | — | — | CN | disclosed |
| CN-1599740-A | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2005-03-23 | — | — | CN | disclosed |
| CN-1599738-A | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2005-03-23 | — | — | CN | disclosed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | disclosed |
| CN-1478090-A | Substituted imidazopyridines | 3M | 2004-02-25 | — | — | CN | disclosed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
| CN-1306442-A | Improement in or relating to contrast agents | NYCOMED INAGING AS (NO) | 2001-08-01 | — | — | CN | disclosed |
| CN-1039016-A | N '-replacement-N, N '-two replaces the hydrazine insect repellent | ROHM & HAAS (US) | 1990-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087585-A1 | Peptide deformylase inhibitors | PDF, DPEP1, PEPD | CA1 4855/4885CA12 4861/4885CA14 4831/4885 |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, SUZ12 | CA1 4703/4885CA12 4782/4885CA14 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.